The stock of Karyopharm Therapeutics Inc. (KPTI) has gone up by 2.04% for the week, with a -33.33% drop in the past month and a -21.38% drop in the past quarter. The volatility ratio for the week is 6.10%, and the volatility levels for the past 30 days are 9.21% for KPTI. The simple moving average for the last 20 days is -12.80% for KPTI stock, with a simple moving average of -38.93% for the last 200 days.
Is It Worth Investing in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Right Now?
while the 36-month beta value is 0.07.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 0 as “sell.”
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
The average price point forecasted by analysts for Karyopharm Therapeutics Inc. (KPTI) is $7.20, which is $4.94 above the current market price. The public float for KPTI is 74.06M, and currently, short sellers hold a 24.25% ratio of that floaft. The average trading volume of KPTI on May 25, 2023 was 2.61M shares.
KPTI) stock’s latest price update
Karyopharm Therapeutics Inc. (NASDAQ: KPTI)’s stock price has plunge by -3.47relation to previous closing price of 2.59. Nevertheless, the company has seen a 2.04% surge in its stock price over the last five trading sessions.
KPTI Trading at -27.03% from the 50-Day Moving Average
After a stumble in the market that brought KPTI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.45% of loss for the given period.
Volatility was left at 9.21%, however, over the last 30 days, the volatility rate increased by 6.10%, as shares sank -30.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.98% lower at present.
During the last 5 trading sessions, KPTI rose by +2.04%, which changed the moving average for the period of 200-days by -51.55% in comparison to the 20-day moving average, which settled at $2.81. In addition, Karyopharm Therapeutics Inc. saw -26.47% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at KPTI starting from Paulson Richard A., who sale 3,805 shares at the price of $3.35 back on May 04. After this action, Paulson Richard A. now owns 812,814 shares of Karyopharm Therapeutics Inc., valued at $12,753 using the latest closing price.
Rangwala Reshma, the EVP & Chief Medical Officer of Karyopharm Therapeutics Inc., sale 6,770 shares at $4.05 during a trade that took place back on Apr 20, which means that Rangwala Reshma is holding 158,230 shares at $27,416 based on the most recent closing price.
Stock Fundamentals for KPTI
Current profitability levels for the company are sitting at:
- -90.53 for the present operating margin
- +96.29 for the gross margin
The net margin for Karyopharm Therapeutics Inc. stands at -105.23. The total capital return value is set at -108.01, while invested capital returns managed to touch -128.07. Equity return is now at value 198.50, with -53.90 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 1.32, with the company’s debt to enterprise value settled at 1.00. The receivables turnover for the company is 4.51 and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.31.
In a nutshell, Karyopharm Therapeutics Inc. (KPTI) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.